Hotspots and prospects of esophageal cancer research in China / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
; (12): 307-311, 2023.
Article
em Zh
| WPRIM
| ID: wpr-986790
Biblioteca responsável:
WPRO
ABSTRACT
Esophageal cancer is a malignant tumor with a high incidence in China. At pesent, advanced esophageal cancer patients are still frequently encountered. The primary treatment for resectable advanced esophageal cancer is surgery-based multimodality therapy, including preoperative neoadjuvant therapy, such as chemotherapy, chemoradiotherapy or chemotherapy plus immunotherapy, followed by radical esophagectomy with thoraco-abdominal two-field or cervico-thoraco-abdominal three-field lymphadenectomy via minimally invasive approach or thoracotomy. In addition, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, or immunotherapy may also be administered if suggested by postoperative pathological results. Although the treatment outcome of esophageal cancer has improved significantly in China, many clinical issues remain controversial. In this article, we summarize the current hotspots and important issues of esophageal cancer in China, including prevention and early diagnosis, treatment selection for early esophageal cancer, surgical approach selection, lymphadenectomy method, preoperative neoadjuvant therapy, postoperative adjuvant therapy, and nutritional support treatment.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Neoplasias Esofágicas
/
Esofagectomia
/
Quimioterapia Adjuvante
/
Terapia Combinada
/
Terapia Neoadjuvante
/
Quimiorradioterapia
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Gastrointestinal Surgery
Ano de publicação:
2023
Tipo de documento:
Article